Clinical Trials · NCT05294536
A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Enrollment
- 50
- Start date
- Jun 2020
- Locations
- 1 site, China
- Primary endpoint
- Maximum (peak) plasma drug concentration(Cmax)